Cardio and pulmonary fibrosis opens up a whole new
Post# of 154090
(Total Views: 1611)
Posted On: 02/06/2025 10:33:02 AM
Cardio and pulmonary fibrosis opens up a whole new ball game. The mention of statistically significant reversal in fibrosis in three different studies is massive And shouldn’t be taken lightly. In fact, if I am a company looking at MASH or fibrosis in any organ system then I am picking up the phone and calling CYDY and saying hey, can we sit down and talk about what you’ve got?
It sounds like there are multiple parties sitting at the table and they haven’t decided on which one yet and because of that they put out a PR to make The shareholders happy. But this also puts the news out to the public and to other big Pharma companies Saying hey, we can reverse fibrosis and we believe we can across multiple organ systems and we are open to discussions about how to move forward with a partnership or partnerships.
No mention of Ozempic is interesting. In the first mouse study, they mentioned Resmiterom (MDGL) And the fact that LL was trending Towards a reversal in fibrosis And now we have statistically significant proof. And the prospectus from last fall said that there was a threefold decrease in fat deposits in the liver . This is also very significant news .
So I am assuming that because they did not mention that they were better than Ozempic there could be a synergistic effect With Ozempic and LL. And that makes me think Novo is still sitting at the table, but CYDY put the data out there to tempt others into a Partnership discussion. Hello Eli Lilly and anyone else looking at fibrosis in other organs!
Partnership/licensing agreements take more time than most people want, and that dreaded anticipation word has to be acknowledged.
This last paragraph reads quite nicely when you think about a partnership:
“The Company intends to explore a number of potential synergies and partnership opportunities in the coming months as it furthers its clinical development pipeline, including opportunities that might explore the potential widespread applications for leronlimab as a treatment path for fibrosis in other organs.”
So they are acknowledging that partnerships take time, and I believe that there are several seats at the table that are filled, and there are more companies wanting to sit down and talk. After this press release, there should be more interest and I’m OK waiting As they entertain discussions and sort through the offers.
Sounds like Jay knows this thing is going to explode and he just telegraphed that to us.
Patience then Patients.
It sounds like there are multiple parties sitting at the table and they haven’t decided on which one yet and because of that they put out a PR to make The shareholders happy. But this also puts the news out to the public and to other big Pharma companies Saying hey, we can reverse fibrosis and we believe we can across multiple organ systems and we are open to discussions about how to move forward with a partnership or partnerships.
No mention of Ozempic is interesting. In the first mouse study, they mentioned Resmiterom (MDGL) And the fact that LL was trending Towards a reversal in fibrosis And now we have statistically significant proof. And the prospectus from last fall said that there was a threefold decrease in fat deposits in the liver . This is also very significant news .
So I am assuming that because they did not mention that they were better than Ozempic there could be a synergistic effect With Ozempic and LL. And that makes me think Novo is still sitting at the table, but CYDY put the data out there to tempt others into a Partnership discussion. Hello Eli Lilly and anyone else looking at fibrosis in other organs!
Partnership/licensing agreements take more time than most people want, and that dreaded anticipation word has to be acknowledged.
This last paragraph reads quite nicely when you think about a partnership:
“The Company intends to explore a number of potential synergies and partnership opportunities in the coming months as it furthers its clinical development pipeline, including opportunities that might explore the potential widespread applications for leronlimab as a treatment path for fibrosis in other organs.”
So they are acknowledging that partnerships take time, and I believe that there are several seats at the table that are filled, and there are more companies wanting to sit down and talk. After this press release, there should be more interest and I’m OK waiting As they entertain discussions and sort through the offers.
Sounds like Jay knows this thing is going to explode and he just telegraphed that to us.
Patience then Patients.
(31)
(0)